Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
RESEARCH TOOLSreports
Holding DE:38I?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-€1.28Last Year’s EPS
-€1.4Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -22.32%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Neutral
The earnings call presented significant progress in Intellia's clinical pipeline and financial management, with notable achievements in CRISPR-based treatments and regulatory clearances. However, challenges such as decreased collaboration revenue and increased operational expenses were also highlighted.Company Guidance
During Intellia Therapeutics' Q3 2024 earnings call, comprehensive guidance was provided, highlighting significant advancements and metrics across their clinical programs. Key developments included unprecedented Phase II results for NTLA-2002, showing that 8 out of 11 patients in the 50-mg cohort were attack-free for hereditary angioedema (HAE), with a planned BLA submission in 2026. The MAGNITUDE-2 Phase III trial for ATTR amyloidosis received FDA clearance, aiming to enroll 50 patients with primary endpoints set at 18 months. Financially, Intellia reported a cash balance of $944.7 million as of September 30, 2024, and expects this to fund operations into late 2026. Collaboration revenue for Q3 was $9.1 million, with R&D expenses at $123.4 million, reflecting increased investment in lead programs. The company continues to lead in the field of in vivo CRISPR-based medicines, with three active Phase III studies anticipated by year-end.Positive Phase II Results for NTLA-2002
Unprecedented positive results from the Phase II study of NTLA-2002 for hereditary angioedema, showing potential for a functional cure with a simple onetime infusion.
FDA Clearance for MAGNITUDE-2 Study
FDA cleared the IND application for the Phase III trial of nex-z for hereditary ATTR amyloidosis with polyneuropathy, marking the fourth consecutive IND clearance within 30 days of submission.
Strong Financial Position
Intellia reported $944.7 million in cash and marketable securities as of September 30, 2024, with a financial runway expected to fund operations into late 2026.
Advancement in Gene Insertion Programs
Progress in in vivo gene insertion programs, particularly NTLA-3001 for alpha-1 antitrypsin deficiency, with plans to dose the first patient in the Phase I/II study by year-end.
Broad Enthusiasm for CRISPR-based Medicines
Progress in three active Phase III studies expected by year-end, indicating leadership in the field of in vivo CRISPR-based medicines.
---
DE:38I Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:38I Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | €14.63 | €15.36 | +4.99% |
| Aug 08, 2024 | €20.45 | €19.23 | -5.97% |
| May 09, 2024 | €21.84 | €22.18 | +1.56% |
| Feb 22, 2024 | €24.71 | €23.91 | -3.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Intellia Therapeutics (DE:38I) report earnings?
Intellia Therapeutics (DE:38I) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Intellia Therapeutics (DE:38I) earnings time?
Intellia Therapeutics (DE:38I) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Intellia Therapeutics stock?
The P/E ratio of Intellia Therapeutics is N/A.
What is DE:38I EPS forecast?
DE:38I EPS forecast for the fiscal quarter 2024 (Q4) is -€1.28.
---